|
| Study | Country | Sample size | Allocation ratio | Type of PO | Age (Year) | Gender (M: F) | Course of the disease (Month) | (A) | (B) | Acupoints selection | Duration of treatment | Follow-up | Efficacy criteria |
| Treatment Group | Control Group I |
|
| Tao et al. [32] | China | 82 | 1 : 1 | SOP | A: 65.3 ± 1.5
B: 64.5 ± 1.3 | A: 19: 22
B: 21: 20 | A: 24–48
B: 24–60 | Mox + CM | CM (calcium supplementation) | Dazhu (BL11), Shenshu (BL23), Pishu (BL20), Zusanli (ST36), Zhongwan (CV12), Guanyuan (CV4) | 90 d | — | 1. Response rate
2. BMD
3. VAS |
|
| Lin et al. [33] | China | 60 | 1 : 1 | PMOP | A: 59.50 ± 5.92
B: 60.75 ± 5.09 | All female | — | Mox + CM | CM (calcium supplementation) | Du Meridian, from Dazhui (GV14) to Yaoshu (GV2) | 90 d | — | 1. VAS |
|
| Tian [34] | China | 60 | 1 : 1 | PO | A: 64.21 ± 6.50
B: 63.59 ± 6.95 | A: 28: 0
B: 26: 1 | A: 22.81 ± 12.30
B: 21.89 ± 11.89 | Mox + CM | CM (calcium supplementation) | Lumbosacral portion from L2 to S1, Pishu (BL20), Shenshu (BL23), Yaoyangguan (GV3), Mingmen (GV4) | 28 d | 30 d | 1. VAS
2. ODI |
|
| Tao [35] | China | 76 | 1 : 1 | PO | A: 69.42 ± 6.27
B: 70.38 ± 6.46 | A: 22: 16
B: 23: 15 | — | Mox | CM (calcium supplementation) | Dazhu (BL11), Shenzhu (GV12), Mingmen (GV4), Shenshu (BL23), Pishu (BL20), Zhongwan (CV12), Shenque (CV8), Zusanli (ST36), Guanyuan (CV4), Xuanzhong (GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Taixi (KI3) | 84 d | — | 1. Response rate
2. BMD |
|
| Gu [36] | China | 60 | 1 : 1 | PMO | A: 60.12 ± 3.67
B: 59.65 ± 3.84 | Allfemale | A: 54.26 ± 3.58
B: 52.78 ± 4.05 | Mox | CM (calcium supplementation) | Shenshu (BL23) | 140 d | — | 1.BMD |
|
| Xu et al. [37] | China | 63 | 32 : 31 | PMO | A: 65.16 ± 6.82
B: 63.90 ± 7.59 | Allfemale | A: 11.31 ± 4.03
B: 11.32 ± 4.06 | Mox + CM | CM (calcium supplementation) | Pishu (BL20), Shenshu (BL23), Yaoyangguan (GV3), Mingmen (GV4) | 28 d | 30 d | 1. VAS |
|
| Wu [38] | China | 60 | 1 : 1 | PMO | 45–65 | Allfemale | >12 | Mox | CM (calcium supplementation) | Pishu (BL20), Shenshu (BL23) | 90 d | — | 1. BMD
2. VAS |
|
| Yang et al. [39] | China | 60 | 1 : 1 | PO | A: 45–80
B: 46–78 | A: 11: 19
B: 12: 18 | A: 24–84
B: 30–78 | Mox + CM | CM (calcium supplementation) | Du Meridian, from Dazhui (GV14) to Yaoshu (GV2) | 84 d | — | 1. Response rate
2. BMD
3. VAS |
|
| Lin et al. [40] | China | 70 | 1 : 1 | PMO | 45–75 | Allfemale | — | Mox + CM | CM (calcium supplementation) | Du Meridian, from Dazhui (GV14) to Yaoshu (GV2) | 90 d | — | 1. VAS
2. ODI |
|
| Ouyang and Xu [41] | China | 60 | 1 : 1 | PMO | 62.45 ± 7.68 | Allfemale | — | Mox + CM | CM (calcium supplementation) | Pishu (BL20), Weishu (BL21), Shenshu (BL23), Mingmen (GV4), Yaoyangguan (GV3), Zhiyang (GV9) | 90 d | — | 1. Response rate |
|
| Ouyang [42] | China | 60 | 1 : 1 | PMO | A: 62.29 ± 7.18
B: 61.14 ± 7.68 | Allfemale | 60 | Mox + CM | CM (calcium supplementation) | Dazhu (BL11), Geshu (BL17), Ganshu (BL18), Shenshu (BL23), Pishu (BL20), Mingmen (GV4), Zusanli (ST36), Yanglingquan (GB34), Taixi (KI3), Guanyuanshu (BL26) | 90 d | — | 1. Response rate
2. BMD
3. VAS |
|
| Ouyang et al. [43] | China | 60 | 1 : 1 | PO | A: 63.25 ± 10.14
B: 60.11 ± 11.35 | A: 12: 18
B: 13: 17 | — | Mox + CM | CM (calcium supplementation) | Dazhu (BL11), Geshu (BL17), Ganshu (BL18), Shenshu (BL23), Pishu (BL20), Mingmen (GV4), Zusanli (ST36), Yanglingquan (GB34), Taixi (KI3), Guanyuanshu (BL26) | 90 d | — | 1. VAS |
|
| Li et al. [44] | China | 60 | 1 : 1 | PO | 40–70 | A: 12: 18
B: 10: 20 | A: 58.92 ± 36.24
B: 60.72 ± 30.12 | Mox | CM (calcium supplementation) | Mingmen (GV4), Shenshu (BL23), Zusanli (ST36), Pishu (BL20) | 117 d | — | 1. Response rate
2. BMD |
|
| Xu and Jin [45] | China | 67 | 36 : 31 | PO | 50–82 | A: 8: 23
B: 9: 27 | A: 87.96 ± 44.04
B: 83.64 ± 33.48 | Mox | CM (calcium supplementation) | Shenque (CV8), Guanyuan (CV4), Qihai (CV6), Mingmen (GV4), Shenshu (BL23), Pishu (BL20) | 90 d | — | 1. Response rate
2. VAS |
|
